Montbretin A (MbA), a natural compound with great potential for the treatment of type-2 diabetes, was discovered in the ornamental plant montbretia ten years ago, but it can’t be produced on a large scale until its biosynthesis is understood. Scientists have now discovered genes and enzymes responsible for MbA biosynthesis and demonstrated the potential for metabolic engineering of wild tobacco to produce this promising drug candidate.